麦科田：拟赴港ipo 加码研发与全球化布局

Core Viewpoint - The company, 麦科田, is a global provider of medical solutions with a comprehensive product portfolio aimed at various clinical needs across healthcare institutions, and it plans to utilize raised funds for R&D, manufacturing expansion, sales enhancement, strategic investments, and IT upgrades [1] Financial Performance - For the fiscal year 2024, the company reported a revenue of 1.399 billion yuan, a year-on-year increase of 6.55%, while the net profit attributable to shareholders was a loss of 96.4 million yuan, compared to a loss of 63.7 million yuan in the previous year [2] - From January 1 to June 30, 2025, the company achieved a revenue of 787 million yuan, reflecting a year-on-year growth of 15.31%, and turned a profit with a net profit of 40.19 million yuan [2] - The operating cash flow for 2024 was 183 million yuan, up 182.75% year-on-year, while for the first half of 2025, it was 56.68 million yuan, down 8.81% year-on-year [6] Asset Changes - As of June 30, 2025, the company's trading financial assets increased by 53.81%, with their proportion of total assets rising by 2.35 percentage points; cash and cash equivalents decreased by 14.5%, with their proportion of total assets falling by 1.72 percentage points [8] - Accounts receivable increased by 37.27%, contributing to a 1.6 percentage point rise in their proportion of total assets, while intangible assets decreased by 2.02%, leading to a 0.89 percentage point drop in their proportion of total assets [8] Liability Changes - As of June 30, 2025, other payables decreased by 26.27%, reducing their proportion of total assets by 2.24 percentage points; however, accounts payable increased by 20.16%, raising their proportion of total assets by 0.94 percentage points [12] - Lease liabilities rose by 21.86%, contributing to a 0.45 percentage point increase in their proportion of total assets, while short-term borrowings increased by 16.5%, leading to a 0.36 percentage point rise in their proportion of total assets [12]